|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Reports suggest that the upregulation of ornithine decarboxylase (ODC) is closely related to carcinogenesis.
|
31793679 |
2020 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated whether ODC may act as a target for chemoprevention in ESCC.
|
31793679 |
2020 |
|
precancerous lesions
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemistry (IHC) assays indicate that ODC expression is higher in esophageal precancerous lesions compared with normal tissue controls.
|
31793679 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, metabolic alterations due to a single copy loss of Ptch1 in Ptch1<sup>+/-</sup>/ODC<sup>t</sup>/C57BL/6 heterozygous mice may provide insights about the cancer prone phenotype of BCCs in GS patients, including biomarkers/targets for early intervention.
|
31506465 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, metabolic alterations due to a single copy loss of Ptch1 in Ptch1<sup>+/-</sup>/ODC<sup>t</sup>/C57BL/6 heterozygous mice may provide insights about the cancer prone phenotype of BCCs in GS patients, including biomarkers/targets for early intervention.
|
31506465 |
2019 |
|
Experimental Organism Basal Cell Carcinoma
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Accordingly, metabolic alterations due to a single copy loss of Ptch1 in Ptch1<sup>+/-</sup>/ODC<sup>t</sup>/C57BL/6 heterozygous mice may provide insights about the cancer prone phenotype of BCCs in GS patients, including biomarkers/targets for early intervention.
|
31506465 |
2019 |
|
Carcinoma, Basal Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, metabolic alterations due to a single copy loss of Ptch1 in Ptch1<sup>+/-</sup>/ODC<sup>t</sup>/C57BL/6 heterozygous mice may provide insights about the cancer prone phenotype of BCCs in GS patients, including biomarkers/targets for early intervention.
|
31506465 |
2019 |
|
Retinoblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Silencing circ_ODC1 resulted in a rise in miR-422a expression and RB cell growth.
|
31297892 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of ODC1 on HCC cell proliferation in vivo was investigated by constructing a xenotransplanted tumor model in nude mice.
|
31239700 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
The roles of ODC1 in HCC cell proliferation, migration and invasion in vitro were investigated using the cell-counting kit-8 assay, 5-ethynyl-2´-deoxyuridine assay, colony formation assay, flow cytometry, wound healing assay and transwell assay, respectively.
|
31239700 |
2019 |
|
Liver carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
The effect of ODC1 on HCC cell proliferation in vivo was investigated by constructing a xenotransplanted tumor model in nude mice.
|
31239700 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Analysis of <i>in vivo</i> metastases and clinical data from patients with prostate cancer support the proposition that the PGC1α/c-MYC/ODC1 axis regulates polyamine biosynthesis and prostate cancer aggressiveness.
|
31064849 |
2019 |
|
Prostate Cancer, Hereditary, 7
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of <i>in vivo</i> metastases and clinical data from patients with prostate cancer support the proposition that the PGC1α/c-MYC/ODC1 axis regulates polyamine biosynthesis and prostate cancer aggressiveness.
|
31064849 |
2019 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Analysis of <i>in vivo</i> metastases and clinical data from patients with prostate cancer support the proposition that the PGC1α/c-MYC/ODC1 axis regulates polyamine biosynthesis and prostate cancer aggressiveness.
|
31064849 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herewith, we investigated the combined effect of TMZ, difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, and radiation in GBM cell lines.
|
30941997 |
2019 |
|
Mechanical Allodynia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The chemopreventive drug α-difluoromethylornithine (DFMO) has been shown to have an antinociceptive effect on mechanical allodynia in inflammatory arthritis by directly inhibiting ornithine decarboxylase (ODC) and decreasing polyamine production in inflammatory sites.
|
30927735 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have shown that the cancer chemopreventive agent α-difluoromethylornithine (DFMO), known to inhibit the enzyme ornithine decarboxylase, reduces <i>H. pylori</i>-mediated gastric cancer incidence in Mongolian gerbils.
|
30804204 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have shown that the cancer chemopreventive agent α-difluoromethylornithine (DFMO), known to inhibit the enzyme ornithine decarboxylase, reduces <i>H. pylori</i>-mediated gastric cancer incidence in Mongolian gerbils.
|
30804204 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our studies reveal that inactive pro-LOX (together with Lox propeptide) functions as a tumor suppressor in ODC- and RAS-transformed murine fibroblasts by inhibiting cell growth and invasion, and active LOX and LOXL2 as tumor promoters in human melanoma cells by promoting their invasive growth.
|
30701028 |
2018 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Thus, our studies reveal that inactive pro-LOX (together with Lox propeptide) functions as a tumor suppressor in ODC- and RAS-transformed murine fibroblasts by inhibiting cell growth and invasion, and active LOX and LOXL2 as tumor promoters in human melanoma cells by promoting their invasive growth.
|
30701028 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment.
|
30700572 |
2019 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment.
|
30700572 |
2019 |
|
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of neuroblastoma cells with the ODC1 inhibitor difluoromethylornithine (DFMO), although a promising therapeutic strategy, is only partially effective at impeding neuroblastoma cell growth due to activation of compensatory mechanisms resulting in increased polyamine uptake from the surrounding microenvironment.
|
30700572 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that CRC cells overexpress ODC and treatment with DFMO decreases cancer hallmarks including enhanced cell proliferation and apoptosis resistance.
|
30642111 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that CRC cells overexpress ODC and treatment with DFMO decreases cancer hallmarks including enhanced cell proliferation and apoptosis resistance.
|
30642111 |
2019 |